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Abstract: Atrial fibrillation (AF) is the most common sustained arrhythmia and a   challenging 
clinical problem encountered in daily clinical practice. There is an increasing body of evi-
dence linking inflammation to a broad spectrum of cardiovascular conditions including AF. 
Historical evidence supports an association between AF and inflammation and is consistent 
with the association of AF with inflammatory conditions of the heart, such as myocarditis and 
pericarditis. AF has been associated with myocardial oxidative stress, and antioxidant agents 
have demonstrated antiarrhythmic benefit in humans. Increased plasma interleukin (IL)-6, 
C-reactive protein (CRP), and plasma viscosity support the existence of an inflammatory state 
among “typical” populations with chronic AF. These indexes of inflammation are related to 
the prothrombotic state and may be linked to the clinical characteristics of the patients (under-
lying vascular disease and comorbidities), rather than simply to the presence of AF itself. It 
has been suggested that inflammation may have a role in the development of atrial arrhythmias 
after cardiac surgery, and that a genetic predisposition to develop postoperative complications 
exists. Cytokines can have a prognostic significance; IL-6 levels, CRP, and other cytokines 
may have prognostic value in AF. Cytokine lowering therapies, statins, angiotensin converting 
enzyme inhibitors and other anti-inflammatory agents may have a role in the treatment of AF. 
The present article provides an overview of the evidence linking inflammatory cytokines to 
AF and their therapeutic and prognostic implications.
Keywords: atrial fibrillation, inflammation, cytokines
Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. 
Its prevalence is strongly age-dependent, affecting approximately 1% of persons 
less than 65-years-old, and 5% of individuals aged older than 65 years. AF is also 
associated with an increase in the relative risk of mortality in both men and women, 
ranging from 1.3 to 2.3, independent of other risk factors, as well as an increasing 
morbidity and adverse affects on quality of life. In particular, patients who present 
with stroke in AF have a considerably worse outcome, defined by a higher mortality, 
morbidity, and longer hospital stays compared with patients who have a stroke in the 
absence of AF.1–5
There is an increasing body of evidence linking inflammation to a broad spec-
trum of cardiovascular conditions, such as coronary artery disease (CAD), insulin 
resistance, diabetes mellitus, and hypertension. In addition, there is emerging data 
to support an association between inflammation and AF. This has created exciting 
potential opportunities to target inflammatory processes for the prevention of AF. Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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AF has been associated with myocardial oxidative stress, 
and antioxidant agents have demonstrated antiarrhythmic 
benefit in humans.
The structural changes of the atria that define structural 
remodeling in AF include left atrial dilatation and increasing 
atrial fibrosis. These structural changes typically occur in par-
allel with changes of the electrical properties of atrial   tissue.6 
In long-lasting persistent AF, lower levels of interleukin 
(IL)-6 and C-reactive protein (CRP) appear to be associated 
with maintenance of sinus rhythm after pharmacological 
cardioversion irrespective of the use of rennin-angiotensin 
system (RAS) inhibitors.7 Radiofrequency ablation gener-
ates a localized myocardial necrosis that might result in a 
release of inflammatory mediators. Limited studies have 
investigated this correlation between inflammatory cytok-
ines and AF. Elevated IL-6 and CRP levels in patients with 
postoperative AF suggest inflammatory components have a 
role in the pathogenesis of post operative AF.8 In addition, 
higher concentrations of serum IL-8 in coronary artery bypass 
graft (CABG) patients with postoperative AF suggested a 
role for inflammation in the pathogenesis of AF after open 
heart surgery.9 Among AF patients, cytokines can have a 
prognostic significance.
The potential for using novel agents that can influence the 
inflammatory processes in AF may represent a shift in the way 
we think of this common arrhythmia, from an electrical to a 
more structural emphasis.10–12 Atrial biopsies from patients 
with AF have confirmed the presence of   inflammation. 
  Furthermore, there is preliminary evidence to support the use 
of a number of drug therapies that have the potential to reduce 
the clinical burden of AF. On the other hand, conflicting 
results exist on the activation of tissue cytokines in fibrillat-
ing atrial samples.13–15 The aim of this article is to present an 
overview of the evidence linking inflammatory cytokines to 
AF. We reviewed pertinent articles published on Medline, 
Pubmed, Scopus and EBSCOhost® research databases till 
December 2009, using the following indexing terms: inflam-
mation, cytokines, AF, and atrial arrhythmias.
Physiological and immunological 
perspectives
Morphological cellular changes in atrial 
fibrillation
The structural changes of the atria that define structural remod-
eling in AF include left atrial dilatation and increasing atrial 
fibrosis. These structural changes typically occur in parallel 
with changes of the electrical properties of atrial tissue. Key 
to this fibrotic process is the deposition of increased amounts 
of connective tissue, including   collagen and fibronectin, 
between individual atrial myocytes. This leads to separation 
of myocytes from one another, and subsequent impairment 
of atrial conduction at the cellular level. All the above result 
in alterations in the biophysical properties of atrial tissue, 
allowing the initiation and perpetuation of AF.6,15–20
Atrial biopsies taken from patients in AF have demon-
strated evidence of inflammatory infiltrates and oxidative 
damage within atrial tissue not seen in control subjects with-
out AF. In one study, abnormal atrial histology was uni-
formly found in multiple biopsy specimens of 12 patients 
with lone AF, compared with normal histology in all of the 
controls, with 66% of the AF group showing evidence of 
occult myocarditis. This supports the view that inflamma-
tion is involved in the pathophysiology of AF.21 Recently, 
activation of the local RAS and mitogen-activated protein 
kinase (MAPK) pathways in atrial myocardium was found 
to play an important role in atrial structural remodeling 
related to AF. Another important mediator of the angiotensin 
II (Ang II) effect is the Janus kinase/signal transducers 
and activators of transcription (STAT) pathway, which has 
never been characterized in the atrium. In cultured atrial 
myocytes and fibroblasts, Ang II induced tyrosine phospho-
rylation of signal transducer and activator of transcription 
3 (STAT3) through a Ras-related C3 botulinum toxin sub-
strate 1 (Rac)1-dependent mechanism, which was inhibited 
by dominant-negative Rac1, losartan, and simvastatin. In 
atrial myocytes, activation of STAT3 by Rac1 was mediated 
by direct association of Rac1 with STAT3; however, in atrial 
fibroblasts, it was mediated by an indirect paracrine effect. 
Constitutively active STAT3 increased protein synthesis, and 
dominant-negative STAT3 abrogated Ang II-induced protein 
synthesis in atrial myocytes and fibroblasts. Rats infused with 
long term Ang II exhibited higher levels of activated Rac1, 
phospho-STAT3, collagen synthesis, and atrial fibrosis in the 
atria, all of which were attenuated by oral losartan and sim-
vastatin. In human atrial tissues from patients with AF, Ang 
II and phospho-STAT3 levels were also elevated. The Ang II/
Rac1/STAT3 pathway is an important signaling pathway in the 
atrial myocardium thought to be involved in atrial structural 
remodeling.22 AF has also been associated with myocardial 
oxidative stress, and antioxidant agents have demonstrated 
antiarrhythmic benefit in humans.23
Oxidative stress and atrial fibrillation)
Infection of endothelial cells with Chlamydia pneumoniae 
elicited the production of several inflammatory mediators 
including monocyte chemoattractant protein-1, IL-1, IL-8, Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
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IL-18, tumor necrosis factor (TNF), interferon and soluble 
intercellular adhesion molecule (Figure 1). Most of these 
cytokines play a crucial role in inflammation and are thought 
to be associated with the initiation and maintenance of AF.24 
Tissue factor expression was observed in the endothelia of 
left atrial appendages obtained from seven patients with 
nonvalvular AF and cardiogenic thromboembolism. Histo-
pathologically, inflammatory cells infiltrated the endocardium 
of all seven patients showing features of persistent myo-
carditis. Activated T cells [15.3 ± 9.4 cells/high power field 
(HPF), (mean ± SD) vs control 2.2 ± 4.4/HPF (P = 0.0294)] 
and a few macrophages [5.1 ± 8.4 cells/HPF vs control 
2.4 ± 3.5 cells/HPF (P = NS)] infiltrated the endocardium. 
Tissue factor was   overexpressed in the endothelia particularly 
in tissues containing inflammatory cells and denuded matrix 
of the endocardium, compared with the control group. Von 
Willebrand factor, but not tissue factor pathway inhibitor, was 
also overexpressed in these tissues.25 Concordant changes 
between matrix metalloproteinase (MMP)-expression and 
fibrosis during mitral valve disease, both in left atrium (LA) 
and right atrium (RA), suggest involvement of MMPs in struc-
tural atrial remodeling. AF itself did not contribute to altered 
fibrosis or MMP-expression in the LA.26 Lipopolysaccharide 
(LPS) infusion is a well established   experimental model used 
to investigate host systemic inflammatory responses. A post 
hoc analysis of prospective data collected for 652 healthy 
Atrial fibrillation (permanent & paroxysmal, post
ablation, post cardioversion, post operative) 
Atrial fibrillation recurrence 
Electrical remolding 
Wave length shorting 
Local & systemic 
oxidative stress
Inflammatory cytokines; IL-1β,
2, 6, 8, 10, 12 CRP, VEGF,
TGF, TNF-α, CD40 
Altered calcium handling
Ca ionic changes 
Figure 1 Role of inflammatory cytokines and oxidative stress in recurrence of atrial fibrillation.
Abbreviations: IL, interleukin; CRP, C-reactive protein; veGF, vascular endothelial growth factor; TGF, transforming growth factor; TNF, tumor necrosis factor.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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men (mean age 27 ± 5 years, all without history of AF) LPS 
led to overall marked increases in high-sensitivity CRP, IL-6, 
TNF-α, and neutrophil counts (all P , 0.0001). There was 
no evidence of new-onset AF in the subjects challenged with 
LPS infusion.27
Atrial fibrillation (AF) has been associated with myo-
cardial oxidative stress, and antioxidant agents have demon-
strated antiarrhythmic benefit in humans. Neuman et al23 
compared serum markers of oxidation and associated 
inflammation in individuals with or without AF. Using serum 
markers of oxidative stress and inflammation, 40 male indi-
viduals – with or without persistent or permanent AF – who 
were matched for age, sex, diabetes, and smoking status, 
known confounding variables, and measurements of oxida-
tive stress, were compared in a cross-sectional, case-control 
design. In this study derivatives of reactive oxidative metabo-
lites (DROMs) and ratios of oxidized to reduced glutathione 
(Eh GSH) and cysteine (Eh CySH) were used to quantify 
oxidative stress. The investigators also measured inflam-
matory markers, including high-sensitivity CRP, IL-1 and 
IL-6, and TNF. Univariate conditional logistical regression 
analysis showed that oxidative stress, but not inflammatory 
markers, were statistically associated with AF (P , 0.05). 
The increase in the odds ratios for AF for Eh GSH, Eh CySH, 
and DROMs were 6.1 (95% CI, 1.3–28.3; P = 0.02), 13.6 
(95% CI, 2.5–74.1; P = 0.01), and 15.9 (95% CI, 1.7–153.9; 
P = 0.02), respectively. In multivariate analysis corrected 
for statins and other AF risk factors there was a stronger 
correlation between Eh GSH and Eh CySH (R = 0.66) than 
between Eh GSH and DROMs (R = 0.41). This study has 
several limitations. First is the small sample size. Neverthe-
less, based on the oxidative stress measure with the weakest 
association to AF (Eh GSH), only 13 individuals in each 
group would have been necessary to have a 90% power to 
detect the observed difference in means with a two-sided test. 
Although the sample size was sufficient to show differences 
between groups in oxidative stress markers, the sample size 
was too small to allow firm conclusions about the relationship 
between inflammatory markers and AF, given their smaller 
means and higher standard deviations. Moreover, all par-
ticipants in this study were males and predominantly white. 
The results may not hold true for females or individuals of 
other races. The effect of medications other than statins or 
the duration of AF on the strength of association between 
oxidative stress and AF were not evaluated. The net number 
of medications was not different between the two groups. 
This study does not make clear the source of oxidative stress 
or how oxidative stress is related to AF.
As noted above, AF has been associated with cardiac 
oxidative stress, but a recent trial suggests that oxidative 
stress in AF may be more widespread. Therefore, it is pos-
sible that systemic oxidative stress contributes to AF risk, 
and, once AF is established, local cardiac oxidative stress 
reinforces the risk.52,28–39 Interestingly, congestive heart failure 
and hypertension are associated with oxidative stress,30–31 
perhaps contributing to their unequal distribution between 
the two groups with and without AF. Finally, the investigators 
measured marker concentrations during usual clinical hours 
and without fasting, mimicking the most common clinical 
scenario. Measuring at other times or under other condi-
tions may affect the results, but there is no known diurnal 
variation in DROM concentrations. There does appear to be 
diurnal variation of plasma-reduced thiols related to meals 
in animals, but the effect of this variation on the ratio of 
oxidized-to-reduced thiols is unknown. In preliminary stud-
ies, diurnal variations in Eh GSH and Eh CySH were too 
small to explain this study’s results and have peaks that are 
separated by 6–7 h, suggesting that the differences observed 
were not the result of these variations alone.32
Different cytokines and atrial  
fibrillation
Seko et al33 reported that pulsatile mechanical stretch in vitro 
induced rapid secretion of vascular endothelial growth 
factor (VEGF) by cultured cardiac myocytes and that the 
stretch-induced secretion of VEGF was mainly mediated 
by secretion of transforming growth factor (TGF)-β1 by 
cardiac myocytes in an autocrine fashion (Tables 1 and 2). 
The above author investigated the serum levels of VEGF 
and TGF-β1 in patients with AF undergoing defibrillation 
therapy. The serum VEGF level before defibrillation was 
significantly increased in 13 out of 20 patients (89.48 ± 
16.09 pg/mL [mean ± standard error of mean, (SE)]). After 
defibrillation, the serum VEGF level in these 13 patients 
significantly (P = 0.019) decreased (65.04 ± 16.61 pg/mL 
[mean ± SE]). The serum TGF-β1 level before defibrilla-
tion therapy (13.01 ± 1.97 pg/mL [mean ± SE]) in these 
12 patients also decreased after defibrillation therapy 
(11.47 ± 2.06 pg/mL [mean ± SE]). The changes in serum 
VEGF level significantly correlated with those in the serum 
TGF-β1 level in these 12 patients (R = 0.73, P , 0.05, 
N = 12). These data suggest that tachyarrhythmia-induced 
mechanical overload can increase the serum VEGF level, 
which can be a useful clinical marker for relative myocar-
dial oxygen shortage in such patients. Tachycardia-induced 
mechanical overload could increase serum VEGF levels in Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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at least some patients with tachyarrhythmia. The secreted 
VEGF may play a role in ameliorating the relative myocardial 
ischemia as well as be one of the most sensitive indicators 
of tachycardia-induced mechanical overload. Recently, it has 
been found that pulsatile mechanical stretch rapidly activated 
intracellular signaling pathways including MAPK family 
members in cultured cardiac myocytes in vitro, and that 
the stretch-induced activation of intracellular signaling was 
mainly mediated by autocrine secretion of VEGF as well as 
TGF-β1 by cardiac myocytes.34–36 These data strongly suggest 
that pulsatile mechanical stretch rapidly stimulates TGF-β1 
secretion from cardiac myocytes, which in turn stimulates 
VEGF secretion, and then secreted VEGF activates intracel-
lular signaling in cardiac myocytes in an autocrine fashion. 
The activated intracellular signaling pathways will cross talk 
with each other and converge to regulate expression of various 
genes to adapt to this external stress. However, considering 
that the elevated serum VEGF levels in patients with acute 
myocardial infarction returned to the normal control range 
within 20 to 30 min after reperfusion,36 it seems that the 
elevated serum VEGF levels in patients with AF also rapidly 
decreased after defibrillation. Although the possibility that 
tachycardia induced mechanical overload actualized subclini-
cal ischemic heart diseases in these patients, an increased 
serum VEGF level sharply reflects direct as well as relative 
myocardial ischemia, and can be a useful clinical marker for 
myocardial oxygen shortage in such patients. In vitro study 
showed that pulsatile mechanical stretch (60 cycles/min for 
5 min, 15% elongation, and 120 cycles/min for 5 min, 10% 
elongation) similarly increased VEGF concentrations in the 
culture media of cardiac myocytes. This suggests that total 
mechanical load, but not pulsatile stretch-rate, regulates 
VEGF secretion from cardiac myocytes. On the other hand, 
pulsatile mechanical stretch (60 cycles/min for 5 min, 15% 
elongation) significantly increased VEGF secretion from 
cardiac myocytes compared with cardiac myocytes without 
stretch, which also contract voluntarily even more frequently 
and more dynamically. This suggests the possibility that pas-
sive or forced contraction but not voluntary contraction can 
stimulate VEGF secretion from cardiac myocytes.34
Increased plasma soluble CD40L (sCD40L) is present 
in many cardiovascular diseases and predicts poor outcome; 
the levels in AF are unknown. Although the platelet is 
frequently cited as the source of sCD40L, this view is not 
universal. Raised sCD40L in nonrheumatic AF, and that 
sCD40L correlates with platelet but not endothelial markers, 
suggests a platelet origin. Plasma sCD40L, platelet marker 
soluble P-selectin, and endothelial markers von Willebrand 
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views on cytokines and atrial fibrillation
factor (vWf) and soluble E-selectin, were measured by 
  enzyme-linked immunosorbent assay (ELISA) in 54 AF 
patients free of diabetes or major cardiovascular disease, and 
in 28 age/sex matched controls. Median (interquartile range) 
sCD40L in AF was 0.82 (0–4.8) ng/mL compared to 0.21 
(0–5.5 ng/mL) in controls (P = 0.0397). vWf and soluble 
P-selectin (P , 0.005), but not soluble E-selectin, were raised 
in AF, but none of the indices intercorrelated significantly. 
sCD40L is marginally raised in AF but the stimulus for 
this is unclear. The lack of clear correlation with relevant 
plasma markers suggests that the source is unlikely to be 
the endothelium or platelet alone.37 In a case-control study 
of 121 patients with AF, (71 “disease control subjects,” and 
56 “healthy control subjects”), AF patients had significantly 
higher sCD40L levels compared to healthy control subjects 
(P = 0.042), with no difference in platelet surface CD40L 
and preformed (p)CD40L levels (total amount of CD40L per 
platelet). A positive correlation was noted between levels 
of sCD40L and pCD40L, and not with soluble P-selectin. 
CD40L-related indexes failed to distinguish between high-
risk and low-risk AF patients. AF patients receiving optimal 
antithrombotic therapy had significantly lower pCD40L 
levels (P , 0.001) compared to control subjects. Optimized 
AF management also resulted in significant reductions in 
the levels of sCD40L (P = 0.023) and pCD40L (P , 0.001). 
While there is a significant, albeit modest, excess of platelet 
activation in AF patients (as measured by sCD40L levels) 
compared to healthy control subjects, this is not in excess 
of that seen in patients with underlying cardiovascular 
diseases.38
Interleukin 6 in atrial fibrillation
IL-6 is a pleiotropic cytokine that has diverse physiological 
roles, including mediation of both proinflammatory responses 
and cytoprotective functions (Table 1). Major studies that 
have investigated the relationship between IL-6 and AF have 
shown significant correlation between the two. In a cross-
sectional analysis of 971 participants in the Heart Soul Study, 
46 of whom had AF, IL-6 was the only biomarker significantly 
associated with AF (median IL-6 3.76 and 2.52 pg/mL in 
those with and without AF, respectively, P = 0.0005; adjusted 
odds ratio 1.77, P = 0.032). The IL-6-174CC genotype 
was significantly associated with the presence of AF in the 
adjusted analysis (odds ratio 2.34, P = 0.04) and with higher 
IL-6 levels (P = 0.002). In the same study, no associations 
were found with other biomarkers, including CRP.39
Whereas in another study, 85 consecutive patients with 
AF serum, high sensitivity (hs)-CRP level was higher 
in overall AF patients than in controls (0.63 ± 0.57 vs 
0.23 ± 0.1 mg/dL, P = 0.001). Similarly, IL-6 level was also 
higher in all AF patients compared with controls (29 ± 36 vs 
11.6 ± 9.7 pg/mL, P = 0.008). In subgroup analysis, hs-CRP 
and IL-6 levels were significantly higher in both chronic 
(0.69 ± 0.62 vs 0.23 ± 0.1 mg/dL, P = 0.001; 30 ± 39 vs 
11.6 ± 9.7 pg/mL, P = 0.001, respectively) and new onset 
AF patients (0.51 ± 0.46 vs 0.23 ± 0.1 mg/dL, P = 0.003; 
28.4 ± 31 vs 11.6 ± 9.7 pg/mL, P = 0.009, respectively) 
compared with controls. These markers were not different 
in new onset and chronic AF subgroups. On the other hand, 
hs-CRP and IL-6 levels tended to be high in lone AF patients 
(P = 0.06). The presence of AF was an independent factor 
for hs-CRP (OR = 0.35, 95% CI = 0.1-0.61, P = 0.005) and 
IL-6 (OR = 17, 95% CI = 1-37, P = 0.037).40
Whether inflammation is a cause or consequence of AF is 
uncertain. Sata et al measured hs-CRP, IL-6, TNF-α before 
and after pharmacological cardioversion in 15 patients with 
paroxysmal AF. Levels of hs-CRP, IL-6, and TNF-α after 
cardioversion were significantly higher in AF patients than 
those in controls (P , 0.05). Furthermore, the levels of 
these indices did not differ significantly even at 24 hours 
and 2 weeks after cardioversion. The limitations of the study 
are the small patient sample size, absence of a histological 
examination of the atrium, and the lack of inflammatory 
parameters before the onset of AF. Hence, additional studies 
in a larger patient cohort are required to resolve these limita-
tions. Although atrial function (functional remodeling) may 
not recover in two weeks, the correlation between inflam-
mation and atrial function is believed to be low. In future 
studies, it will be necessary to investigate the correlation 
between inflammation and the recovery of atrial function. 
Because inflammation may be caused by other factors, and 
the other causes of AF remain largely unknown.41
AF produces a characteristic profile of gene-expression 
changes that may be related to the pathophysiology of 
the arrhythmia. This has been demonstrated in right atrial 
appendages from 11 patients with chronic AF and underlying 
valvular heart disease (AF-VHD) and seven patients in sinus 
rhythm (SR) with VHD (SR-VHD) who were individually 
compared to an age-matched sinus-rhythm control group 
(SR-CTRL, 11 patients) using cardiac-specific microar-
ray analysis (confirmed by quantitative polymerase chain 
reaction [PCR]). Out of 3863 analyzed genes, 832 genes 
were differentially expressed between SR-VHD and SR-
CTRL patients, and 169 genes were differentially expressed 
between AF-VHD and SR-VHD patients. AF-related changes 
included altered expression of nine genes pointing towards Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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views on cytokines and atrial fibrillation
the development of fibrosis (eg, upregulation of TGF-β1), 
and changes in eight genes potentially related to an increased 
risk of thromboembolic events (eg, upregulation of α-2-
macroglobulin[α2m]).42
Atrial fibrillation and inflammation: role 
of C-reactive protein
CRP has both proinflammatory and anti-inflammatory 
actions. Proinflammatory effects include the induction in 
monocytes of inflammatory cytokines and tissue factor and 
shedding of the IL-6 receptor. The association between AF 
and inflammation is suggested by the frequent association 
of AF with inflammatory conditions of the heart, such as 
myocarditis and pericarditis.43,44
Bruins and colleagues13 were the first to propose the 
inflammation–AF hypothesis, following their observations 
of an increased frequency of AF after coronary artery bypass 
surgery. They noted that the peak incidence of AF occurred 
on the second and third postoperative days, which coincided 
with the peak elevation of CRP levels. In an interesting 
study by Maixent and colleagues45 the authors demonstrated 
the presence of circulating autoantibodies against myosin 
heavy chain in a significant percentage of patients with 
idiopathic paroxysmal AF, which raises the possibility of 
an inflammatory autoimmune process in some patients with 
paroxysmal AF.
CRP, a biomarker of inflammation, has been reported 
to be elevated in some patients with AF. Statins and anti-
oxidants may prevent AF through anti-inflammatory and/
or antioxidant effects.40,46–51 The precise mechanism for the 
increased circulating levels of CRP in AF is uncertain, but 
might reflect active participation of CRP in the local inflam-
matory response within the atrial myocardium. In patients 
with AF, CRP may localize in atrial tissue, possibly binding 
to the membranes of myocardial cells in inflamed tissues and 
activating complement, leading to tissue damage.52,53 Serum 
levels of hs-CRP have been noted to be higher among patients 
with AF compared with controls in sinus rhythm.23,47,54–58 
hs-CRP has also been shown to be predictive of subsequent 
development of AF among a large cohort of patients in sinus 
rhythm at baseline. In addition, patients with persistent AF 
have higher hs-CRP levels than patients with paroxysmal 
AF, and both groups have higher levels than controls without 
AF. 48 In one study, the combination of microalbuminuria 
and an elevated hs-CRP increased the risk of subsequent AF 
development by up to four-fold.59
Furthermore, a longer duration of AF is associated with 
higher hs-CRP levels and larger left atrial dimensions, 
supporting a link between the burden of AF, inflamma-
tion, and structural remodeling. In both cross sectional and 
longitudinal studies, hs-CRP has been consistently and 
significantly predictive of early AF relapse after success-
ful cardioversion, even after adjustment for risk factors for 
AF, such as hypertension and CAD. Furthermore ablation 
induces an acute inflammatory upregulation reflected by an 
increase of CRP and fibrinogen levels and of the leukocyte 
count.50,22,58,14,60,61
Inflammatory cytokines and atrial fibrillation in 
experimental studies
Inflammation and abnormal calcium homeostasis play 
important roles in AF. In isolated rabbit pulmonary vein 
(PV) cardiomyocytes, TNF-α, a proinflammatory cytokine, 
can increase PV arrhythmogenicity and induce an abnormal 
calcium homeostasis, thereby causing inflammation-related 
AF (Table 3). Compared with control PV cardiomyocytes 
(N = 45), the TNF-α-treated PV cardiomyocytes (N = 28) had 
significantly larger amplitudes of delayed after depolariza-
tions, smaller L-type calcium currents, larger transient inward 
currents, larger Na(+)-Ca(2+) exchanger currents, a smaller 
intracellular calcium transient, smaller sarcoplasmic reticu-
lum calcium content, larger diastolic intracellular calcium, 
a longer decay portion of the calcium transient (Tau), and 
a decreased sarcoplasmic reticulum adenosine triphosphate 
(ATP)ase expression.62
Recombinant human (rh)IL-11 in old rats induces age-
dependent atrial remodeling manifested by atrial stretch 
and reduced atrial refractoriness, which favor AF. Na reten-
tion is the most likely mechanism underlying this effect of 
rhIL-11.63 Whether increased fibrosis in atrial tissue without 
ventricular fibrosis is sufficient to produce a substrate for AF 
was evaluated by Verheule et al.64 The authors studied cardiac 
electrophysiology (EP) and inducibility of atrial arrhythmias 
in major histocompatibility complex (MHC)-transforming 
growth factor (TGF)-cys33ser transgenic mice (Tx), which 
have increased fibrosis in the atrium but not in the ventricles. 
In anesthetized mice, wild-type (Wt) and Tx did not show 
significant differences in surface electrocardiogram (ECG) 
parameters. With transesophageal atrial pacing, no significant 
differences were observed in EP parameters, except for a 
significant decrease in corrected sinus node recovery time 
in Tx mice. Burst pacing induced AF in 14 of 29 Tx mice, 
whereas AF was not induced in Wt littermates (P , 0.01). In 
Langendorff perfused hearts, atrial conduction was studied 
using a 16-electrode array. Epicardial conduction velocity 
was significantly decreased in the Tx RA compared with Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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the Wt RA. In the Tx LA, conduction velocity was not 
significantly different from Wt, but conduction was more 
heterogeneous. Action potential characteristics recorded 
with intracellular microelectrodes did not reveal differences 
between Wt and Tx mice in either atrium. Thus, in this trans-
genic mouse model, selective atrial fibrosis was sufficient to 
increase AF inducibility.
In human studies, gene expression of collagen type I 
and IL-1β is altered in patients with AF. Right atrial tissue 
samples were taken from 75 patients with rheumatic heart 
disease who underwent heart valve replacement surgery. 
The messenger ribonucleic acid (mRNA) content of col-
lagen type I was significantly increased in the persistent 
AF group (P , 0.001) and increased in the paroxysmal AF 
group (P , 0.05) as compared with that in the sinus rhythm 
group. The mRNA content of IL-1β was up-regulated in the 
persistent AF group (P , 0.05).65
Clinical perspectives
Role of cytokines after cardioversion
In long-lasting persistent AF, lower levels of IL-6 and CRP 
appear to be associated with maintenance of sinus rhythm 
after pharmacological cardioversion irrespective of the use of 
RAS inhibitors. In 35 consecutive patients with AF7 lasting $ 
1 month who had successful pharmacological cardioversion 
with bepridil alone or in combination with aprindine, both 
plasma levels of IL-6 and CRP were significantly lower in 
20 patients who maintained sinus rhythm than in 15 patients 
who had recurrence of AF (IL-6: 1.19 ± 0.51 versus 1.84 ± 
0.66 ng/L, P , 0.005; CRP: 0.59 ± 0.40 versus 1.24 ± 
0.79 mg/L, P , 0.005). In another study in patients with 
hypertension and/or chronic stable CAD and symptomatic 
recent onset AF (86 patients), low serum IL-2 levels on 
admission were associated with successful cardioversion 
with amiodarone. Multivariate logistic regression analysis 
showed that lower IL-2 admission levels were a powerful 
independent predictor for successful cardioversion (OR: 
0.154, 95% CI: 0.043–0.552, P = 0.004). This observation 
highlights the role of inflammation in AF and might have 
further prognostic and therapeutic implications.66
Inflammatory markers, and their role in maintaining sinus 
rhythm after electrical cardioversion for AF, and the effect 
of candesartan were investigated in a double-blind placebo-
controlled study Candesartan in the Prevention of Relapsing 
Atrial Fibrillation (CAPRAF)67 in which 171 patients with 
persistent AF were randomly assigned to receive candesartan 
8 mg/day or placebo for 3 to 6 weeks before, and cande-
sartan 16 mg/day or placebo for 6 months after,   electrical 
  cardioversion, Compared with patients with a relapse of 
AF, patients who maintained sinus rhythm at 6 months 
after cardioversion (N = 40) had lower baseline hs-CRP and 
E-selectin levels: median 2.36 mg/L (25th, 75th percentiles 
1.28, 4.09) versus 3.44 mg/L (25th, 75th percentiles 1.66, 
6.05, P = 0.031) and 32 ng/mL (25th, 75th percentiles 23, 42) 
versus 37 ng/mL (25th, 75th percentiles 28, 51, P = 0.042), 
respectively. Neither sustained sinus rhythm for 6 months nor 
did treatment with candesartan have an impact on measured 
concentrations of markers of inflammation. The CAPRAF 
study concluded that low hs-CRP and E-selectin at baseline 
were associated with maintenance of sinus rhythm after 
electrical cardioversion.
Serum hepatocyte growth factor (HGF) is considered 
to be a potent marker of vascular endothelial injury. Serum 
HGF levels increase in AF and decrease after successful 
direct-current (DC) cardioversion. Katoh et al68 studied 
39 patients with AF in whom sinus rhythm was maintained 
for at least 7 days after DC cardioversion. Serum HGF levels 
were significantly higher in the AF patients (both lone 
AF and with underlying heart disease) than in the controls 
(0.16 ± 0.07 vs 0.10 ± 0.04 ng/mL; P , 0.001). Seven days 
after successful DC cardioversion, the patients’ serum HGF 
levels had decreased significantly (0.16 ± 0.07 vs 0.12 ± 
0.06 ng/mL; P , 0.05) and in the 24 patients maintaining 
sinus rhythm 1 month after DC cardioversion, serum HGF 
levels decreased to control values (0.10 ± 0.08 ng/mL at 
1 month). Serum HGF levels of the 15 patients who had 
relapsed into AF 1 month after DC cardioversion tended 
to decrease 7 days after DC cardioversion, but increased 
again 1 month after DC cardioversion. This study is the 
first to demonstrate that serum HGF levels increase in AF 
and decrease after successful DC cardioversion. This may 
reflect the fact that AF induces vascular endothelial injury. 
In another study the levels of β-thromboglobulin (βTG) and 
platelet factor 4 (PF4) during tachyarrhythmia (in 15 patients 
with paroxysmal AF [PAF] [9 men, mean age 45 ± 11], and 
14 patients with paroxysmal supraventricular tachycardia 
[PSVT] [8 men, mean age 40 ± 10]), there was no platelet 
activation in patients with PSVT during tachyarrhythmia, 
but significantly increased platelet activity in paroxysmal AF 
and chronic AF patients. There was a significant decrement 
of the platelet activity to a level of control subjects 24 hours 
after cardioversion of PAF.69
Abnormal hemorheology appears to play an important 
role in patients with paroxysmal AF, especially during 
the paroxysms of AF. Cardioversion of persistent AF to 
sinus rhythm appears to decrease the platelet activation, Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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but whether this translates into a beneficial reduction in 
thromboembolic risk is unknown.70 Injury to the heart causes 
hematopoietic progenitor cells (HPCs) to migrate to the site 
of damage and to undergo cell differentiation. Studies suggest 
that myocardial progenitor cells invade atrial tissue. So far it 
is unclear,   however, whether an atrial disease per se affects 
circulating HPCs. In a small sample size study of 17 patients 
with   persistent AF, 12 with PAF, and 17 matched patients 
with sinus rhythm, HPCs (CD34 and CD34+/CD117+) were 
quantified with the use of a fluorescence-activated cell sorter; 
stromal cell derived (SDF) factor-1 (SDF-1α), VEGF, and 
atrial natriuretic peptide (ANP), were determined by immu-
noassays. In patients with persistent AF, blood samples 
obtained before as well as 10 minutes, 24 hours, and 48 hours 
after electrical cardioversion CD34+ HPCs (P , 0.01) were 
increased during persistent AF only. Highest SDF-1α levels 
were also observed during persistent AF. Successful and unsuc-
cessful cardioversion decreased CD34+ HPCs temporarily 
(P = 0.05). Forty-eight hours after successful cardioversion, 
SDF-1 and CD34+ HPC levels started to decline, reaching 
control levels after 59 ± 19 days. CD34+/CD117+ and VEGF 
levels were increased by DC energy but not by AF. ANP 
levels correlated with CD34+ HPC (R = 0.76; P = 0.01) and 
SDF-1α (R = 0.56; P = 0.01). HPCs from patients with AF 
had a greater tendency to differentiate into cells expressing 
cardiomyocyte markers ANP and myocyte enhancer factor-2. 
Persistent AF appears to increase the potential of HPCs for 
cardiomyogenesis. Restitution of CD34+ HPC levels, medi-
ated by SDF-1 and possibly ANP, occurs within several 
weeks after successful cardioversion.71
Role of cytokines after atrial fibrillation 
ablation
Radiofrequency ablation generates a localized myocardial 
necrosis that might result in a release of inflammatory 
mediators (Table 4). Limited studies have investigated the 
potential role of inflammatory cytokines and catheter-based 
radiofrequency ablation of AF. Liuba et al72 studied 29 
patients referred for radiofrequency catheter ablation: 10 
patients with paroxysmal AF, 8 patients with permanent AF, 
and 10 control patients with Wolff-Parkinson-White (WPW) 
syndrome and no evidence of AF (mean age 54 ± 11 vs 
57 ± 13 vs 43 ± 16). Compared with controls and patients 
with paroxysmal AF, patients with permanent AF had higher 
plasma levels of IL-8 in the samples from the femoral vein, 
right atrium, and coronary sinus, but not in the samples from 
the pulmonary veins (median values in the femoral vein: 
2.58 vs 2.97 vs 4.66 pg/mL, P = 0.003; right atrium: 2.30 vs 
3.06 vs 3.93 pg/mL, P = 0.013;   coronary sinus: 2.85 vs 3.15 
vs 4.07, P = 0.016). A high degree of   correlation existed 
between the IL-8 levels in these samples (correlation coef-
ficient between 0.929 and 0.976, P , 0.05). No differences 
in the CRP and IL-6 levels were noted between the three 
groups of patients.
IL-6, IL-1β, TNF-α, IL-8, IL-10, and IL-12, and SDF-1 
were measured by immunoassay by Stein et al73 in patients 
with paroxysmal AF before and after PV isolation. CD34+, 
CD133+, CD117+, and endothelial progenitor cells (EPCs) 
were analysed by flow cytometry and culture assay. Myo-
cardial necrosis and inflammatory response correlated with 
an increase in IL-6 (P = 0.007). In contrast, SDF-1 levels 
decreased after radiofrequency ablation (P = 0.004). Yet, no 
significant changes were observed in IL-1β, TNF-α, IL-8, 
IL-10, and IL-12 plasma levels or in the number of circulating 
CD34+, CD133+ and CD117+ progenitor cells.
CRP and IL-6 levels are also elevated in patients present-
ing in atrial flutter (AFL). Given the lower coronary sinus 
concentrations of these inflammatory markers in such patients, 
their origin appears to be systemic rather than cardiac. This 
was shown in a prospective observational study74 wherein CRP 
and IL-6 levels from the femoral vein and coronary sinus were 
compared before curative ablation for AFL (N = 59) and parox-
ysmal supraventricular tachycardia (SVT) (N = 110). Follow-
up levels were obtained at 1 and 6 months after ablation. Both 
CRP and IL-6 were significantly lower in the coronary sinus 
than in the periphery (P = 0.0076 and 0.0021, respectively) 
in the AFL group. CRP has a significantly lower median of 
47 days after AFL ablation (from a median of 6.28 mg/L to 
a median of 2.92 mg/L; P = 0.028), and remained reduced at 
second follow-up. IL-6 decreased across three time points after 
AFL ablation (P = 0.002). Levels of each marker were similar 
in the coronary sinus and peripheral blood in the SVT group; 
and no reduction in inflammatory biomarkers was observed 
after SVT ablation. Because these levels significantly fall after 
ablation of AFL, the atrial tachyarrhythmia appears to be the 
cause (not the result) of the inflammation.
Role of cytokines in postoperative atrial 
fibrillation
Elevated IL-6 and hs-CRP levels in patients with postoperative 
AF suggest inflammatory components have a role in the patho-
genesis of post operative AF (Table 5).8 In addition, higher con-
centrations of serum IL-8 in CABG patients with postoperative 
AF suggested a role for inflammation in the pathogenesis of 
AF after open heart surgery. Wu et al studied the relation of 
postoperative new AF and systemic   inflammatory changes Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
87
views on cytokines and atrial fibrillation
T
a
b
l
e
 
4
 
I
n
fl
a
m
m
a
t
o
r
y
 
c
y
t
o
k
i
n
e
s
 
a
n
d
 
a
t
r
i
a
l
 
fi
b
r
i
l
l
a
t
i
o
n
 
a
b
l
a
t
i
o
n
A
u
t
h
o
r
P
a
t
i
e
n
t
s
 
s
t
u
d
i
e
d
C
y
t
o
k
i
n
e
s
 
s
t
u
d
i
e
d
R
e
s
u
l
t
s
L
i
u
b
a
 
e
t
 
a
l
 
2
0
0
8
7
2
2
9
 
p
a
t
i
e
n
t
s
 
r
a
d
i
o
f
r
e
q
u
e
n
c
y
 
c
a
t
h
e
t
e
r
 
a
b
l
a
t
i
o
n
:
 
1
0
 
p
a
r
o
x
y
s
m
a
l
 
A
F
,
 
8
 
p
a
t
i
e
n
t
s
 
p
e
r
m
a
n
e
n
t
 
A
F
,
 
a
n
d
 
1
0
 
c
o
n
t
r
o
l
 
w
P
w
 
s
y
n
d
r
o
m
e
 
p
a
t
i
e
n
t
s
.
h
s
-
C
R
P
,
 
I
L
-
6
,
 
a
n
d
 
I
L
-
8
 
i
n
 
t
h
e
 
f
e
m
o
r
a
l
 
v
e
i
n
,
 
R
A
,
 
C
S
,
 
l
e
f
t
 
a
n
d
 
r
i
g
h
t
 
u
p
p
e
r
 
P
v
–
 
 
P
a
t
i
e
n
t
s
 
w
i
t
h
 
p
e
r
m
a
n
e
n
t
 
A
F
 
h
a
d
 
h
i
g
h
e
r
 
p
l
a
s
m
a
 
l
e
v
e
l
s
 
o
f
 
I
L
-
8
 
i
n
 
t
h
e
 
s
a
m
p
l
e
s
 
f
r
o
m
 
t
h
e
 
f
e
m
o
r
a
l
 
v
e
i
n
,
 
R
A
 
a
n
d
 
c
o
r
o
n
a
r
y
 
s
i
n
u
s
,
 
b
u
t
 
n
o
t
 
i
n
 
t
h
e
 
s
a
m
p
l
e
s
 
f
r
o
m
 
t
h
e
 
P
v
.
 
N
o
 
d
i
f
f
e
r
e
n
c
e
s
 
h
s
-
C
R
P
 
a
n
d
 
I
L
-
6
 
i
n
 
t
h
r
e
e
 
g
r
o
u
p
s
.
S
t
e
i
n
 
e
t
 
a
l
 
2
0
0
8
7
3
P
a
r
o
x
y
s
m
a
l
 
A
F
 
p
a
t
i
e
n
t
s
 
b
e
f
o
r
e
 
a
n
d
 
a
f
t
e
r
 
 
P
v
 
i
s
o
l
a
t
i
o
n
I
L
-
6
,
 
I
L
-
1
β
,
 
T
N
F
-
α
,
 
I
L
-
8
,
 
I
L
-
1
0
,
 
I
L
-
1
2
,
 
S
D
F
-
1
 
b
y
 
i
m
m
u
n
o
a
s
s
a
y
.
 
C
D
3
4
+
C
D
1
3
3
+
,
 
C
D
1
1
7
+
,
 
a
n
d
 
e
P
C
s
–
 
 
L
e
u
k
o
c
y
t
e
 
c
o
u
n
t
s
 
a
n
d
 
C
R
P
 
a
n
d
 
I
L
-
6
 
l
e
v
e
l
s
 
↑
 
s
i
g
n
i
fi
c
a
n
t
l
y
.
 
–
 
M
y
o
c
a
r
d
i
a
l
 
n
e
c
r
o
s
i
s
 
a
n
d
 
i
n
fl
a
m
m
a
t
o
r
y
 
r
e
s
p
o
n
s
e
 
c
o
r
r
e
l
a
t
e
d
 
w
i
t
h
 
↑
 
i
n
 
I
L
-
6
 
(
P
 
=
 
0
.
0
0
7
)
.
 
–
 
S
D
F
-
1
 
l
e
v
e
l
s
 
↓
 
a
f
t
e
r
 
R
F
 
a
b
l
a
t
i
o
n
 
(
P
 
=
 
0
.
0
0
4
)
.
 
–
 
 
I
L
-
1
β
,
 
T
N
F
-
α
,
 
I
L
-
8
,
 
I
L
-
1
0
,
 
I
L
-
1
2
 
p
l
a
s
m
a
 
l
e
v
e
l
s
,
 
c
i
r
c
u
l
a
t
i
n
g
 
C
D
3
4
+
 
C
D
1
3
3
+
 
a
n
d
 
C
D
1
1
7
+
 
p
r
o
g
e
n
i
t
o
r
 
c
e
l
l
s
 
n
o
t
 
a
f
f
e
c
t
e
d
.
P
o
l
y
a
k
o
v
a
 
e
t
 
a
l
 
2
0
0
8
7
5
B
i
o
p
s
i
e
s
 
R
A
A
 
+
 
R
F
w
 
2
4
 
p
a
t
i
e
n
t
s
 
 
w
i
t
h
 
A
F
 
h
a
v
e
 
m
i
n
i
-
M
a
z
e
 
p
r
o
c
e
d
u
r
e
 
 
+
 
2
4
 
p
a
t
i
e
n
t
s
 
i
n
 
S
R
C
o
l
l
a
g
e
n
 
t
y
p
e
 
I
 
a
n
d
 
I
I
I
 
s
y
n
t
h
e
s
i
s
/
d
e
g
r
a
d
a
t
i
o
n
,
 
T
G
F
-
β
1
–
 
 
T
I
M
P
2
 
e
n
h
a
n
c
e
d
 
o
n
l
y
 
i
n
 
R
A
A
-
A
F
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
S
R
 
–
 
C
o
l
l
a
g
e
n
 
v
I
,
 
M
M
P
2
,
 
M
M
P
9
 
a
n
d
 
T
I
M
P
1
 
↑
,
 
–
 
 
R
e
C
K
 
a
 
n
e
w
l
y
 
d
i
s
c
o
v
e
r
e
d
 
M
M
P
s
 
i
n
h
i
b
i
t
o
r
,
 
↑
 
i
n
 
R
F
w
 
c
o
m
p
a
r
e
d
 
t
o
 
R
A
A
-
A
F
 
(
P
 
,
 
0
.
0
5
)
 
a
n
d
 
R
F
w
-
S
R
 
(
P
 
,
 
0
.
0
5
)
,
 
–
 
T
G
F
-
β
1
 
↑
 
i
n
 
A
F
.
M
a
r
c
u
s
 
e
t
 
a
l
 
2
0
0
8
7
4
A
 
p
r
o
s
p
e
c
t
i
v
e
 
o
b
s
e
r
v
a
t
i
o
n
a
l
 
s
t
u
d
y
 
i
n
 
 
5
9
 
a
t
r
i
a
l
 
fl
u
t
t
e
r
 
p
a
t
i
e
n
t
s
,
 
S
v
T
;
 
(
N
 
=
 
1
1
0
)
.
 
F
o
l
l
o
w
-
u
p
 
l
e
v
e
l
s
 
1
 
a
n
d
 
6
 
m
o
n
t
h
s
C
R
P
 
a
n
d
 
I
L
-
6
 
l
e
v
e
l
s
 
i
n
 
f
e
m
o
r
a
l
 
v
e
i
n
 
a
n
d
 
C
S
 
b
e
f
o
r
e
 
c
u
r
a
t
i
v
e
 
a
b
l
a
t
i
o
n
 
f
o
r
 
A
F
L
–
 
 
A
F
L
 
p
a
t
i
e
n
t
s
 
h
a
d
 
↑
 
C
R
P
 
l
e
v
e
l
s
,
 
–
 
C
R
P
 
a
n
d
 
I
L
-
6
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
l
o
w
e
r
 
i
n
 
t
h
e
 
C
S
 
v
s
 
p
e
r
i
p
h
e
r
y
,
 
–
 
 
C
R
P
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
l
o
w
e
r
 
a
t
 
a
 
m
e
d
i
a
n
 
o
f
 
4
7
 
d
a
y
s
 
a
f
t
e
r
 
A
F
L
 
a
b
l
a
t
i
o
n
.
 
–
 
 
I
L
-
6
 
↓
 
a
c
r
o
s
s
 
3
 
t
i
m
e
 
p
o
i
n
t
s
 
a
f
t
e
r
 
A
F
L
 
a
b
l
a
t
i
o
n
.
 
–
 
L
e
v
e
l
s
 
o
f
 
e
a
c
h
 
m
a
r
k
e
r
 
w
e
r
e
 
s
i
m
i
l
a
r
 
i
n
 
t
h
e
 
C
S
 
a
n
d
 
p
e
r
i
p
h
e
r
a
l
 
b
l
o
o
d
 
i
n
 
t
h
e
 
S
v
T
 
g
r
o
u
p
.
T
v
e
i
t
 
e
t
 
a
l
 
2
0
0
7
6
7
1
7
1
 
p
e
r
s
i
s
t
e
n
t
 
A
F
 
p
a
t
i
e
n
t
s
 
r
a
n
d
o
m
l
y
 
t
o
 
c
a
n
d
e
s
a
r
t
a
n
 
8
 
m
g
/
d
a
y
 
o
r
 
p
l
a
c
e
b
o
/
3
-
6
 
w
k
s
 
b
e
f
o
r
e
 
a
n
d
 
1
6
 
m
g
/
d
a
y
 
o
r
 
p
l
a
c
e
b
o
 
f
o
r
 
6
 
m
o
n
t
h
s
 
a
f
t
e
r
 
e
l
e
c
t
r
i
c
 
C
v
.
 
D
o
u
b
l
e
-
b
l
i
n
d
 
p
l
a
c
e
b
o
-
c
o
n
t
r
o
l
l
e
d
 
s
t
u
d
y
 
(
C
A
P
R
A
F
)
S
e
r
u
m
 
l
e
v
e
l
s
 
o
f
 
h
s
-
C
R
P
,
 
T
N
F
-
α
,
 
I
L
-
6
,
 
P
-
s
e
l
e
c
t
i
n
,
 
e
-
s
e
l
e
c
t
i
n
,
 
 
C
D
-
4
0
L
,
 
v
C
A
M
-
1
–
 
 
P
a
t
i
e
n
t
s
 
i
n
 
S
R
 
a
t
 
6
 
m
o
n
t
h
s
 
a
f
t
e
r
 
C
v
 
(
N
 
=
 
4
0
)
 
h
a
d
 
l
o
w
e
r
 
b
a
s
e
l
i
n
e
 
h
s
-
C
R
P
 
a
n
d
 
e
-
s
e
l
e
c
t
i
n
 
l
e
v
e
l
s
:
 
m
e
d
i
a
n
 
2
.
3
6
 
m
g
/
L
 
v
e
r
s
u
s
 
3
.
4
4
 
m
g
/
L
 
(
P
 
=
 
0
.
0
3
1
)
 
a
n
d
 
3
2
 
n
g
/
m
l
 
v
e
r
s
u
s
 
3
7
 
n
g
/
m
l
 
 
(
P
 
=
 
0
.
0
4
2
)
,
 
r
e
s
p
e
c
t
i
v
e
l
y
.
R
i
z
o
s
 
e
t
 
a
l
 
2
0
0
7
6
6
8
6
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
s
y
m
p
t
o
m
a
t
i
c
 
r
e
c
e
n
t
 
 
o
n
s
e
t
 
A
F
 
+
 
H
T
N
 
a
n
d
/
o
r
 
s
t
a
b
l
e
 
C
A
D
I
L
-
2
,
 
I
L
-
6
,
 
h
s
-
C
R
P
–
 
 
M
e
d
i
a
n
 
s
e
r
u
m
 
I
L
-
2
 
l
e
v
e
l
s
 
o
n
 
a
d
m
i
s
s
i
o
n
 
w
e
r
e
 
h
i
g
h
e
r
 
i
n
 
n
o
n
-
c
a
r
d
i
o
v
e
r
t
e
d
 
v
s
 
c
a
r
d
i
o
v
e
r
t
e
d
 
p
a
t
i
e
n
t
s
 
(
P
 
=
 
0
.
0
0
2
)
.
 
A
t
 
4
8
h
,
 
–
 
n
o
n
-
c
a
r
d
i
o
v
e
r
t
e
d
 
h
a
d
 
h
i
g
h
e
r
 
I
L
-
6
 
(
P
 
=
 
0
.
0
0
5
)
 
a
n
d
 
h
s
-
C
R
P
 
v
a
l
u
e
s
,
 
P
 
=
 
0
.
0
0
1
)
.
P
s
y
c
h
a
r
i
 
e
t
 
a
l
 
2
0
0
5
5
8
P
r
o
s
p
e
c
t
i
v
e
 
s
t
u
d
y
 
o
f
 
9
0
 
p
a
t
i
e
n
t
s
 
w
i
t
h
 
p
e
r
s
i
s
t
e
n
t
 
a
n
d
 
p
e
r
m
a
n
e
n
t
 
A
F
 
a
n
d
 
 
4
6
 
c
o
n
t
r
o
l
s
C
-
r
e
a
c
t
i
v
e
 
p
r
o
t
e
i
n
 
a
n
d
 
I
L
-
6
–
 
 
(
C
R
P
)
 
a
n
d
 
I
L
-
6
 
l
e
v
e
l
s
 
i
n
 
A
F
 
p
a
t
i
e
n
t
s
 
c
o
m
p
a
r
e
d
 
w
i
t
h
 
c
o
n
t
r
o
l
s
 
(
P
 
,
 
0
.
0
0
1
)
.
–
 
 
C
R
P
 
i
s
 
i
n
d
e
p
e
n
d
e
n
t
 
p
r
e
d
i
c
t
o
r
 
o
f
 
A
F
 
b
y
 
m
u
l
t
i
v
a
r
i
a
t
e
 
a
n
a
l
y
s
i
s
 
(
P
 
=
 
0
.
0
1
)
.
 
–
 
I
L
-
6
 
l
e
v
e
l
s
 
p
o
s
i
t
i
v
e
l
y
 
r
e
l
a
t
e
d
 
t
o
 
A
F
 
d
u
r
a
t
i
o
n
 
b
e
f
o
r
e
 
c
a
r
d
i
o
v
e
r
s
i
o
n
 
(
P
 
=
 
0
.
0
2
)
.
K
a
t
o
h
 
e
t
 
a
l
 
2
0
0
4
6
8
3
9
 
A
F
 
p
a
t
i
e
n
t
s
 
i
n
 
S
R
 
7
 
d
a
y
s
 
a
f
t
e
r
 
D
C
 
 
C
v
 
+
 
3
0
 
a
g
e
-
 
a
n
d
 
s
e
x
-
m
a
t
c
h
e
d
 
n
o
r
m
a
l
 
c
o
n
t
r
o
l
 
i
n
 
S
R
S
e
r
u
m
 
H
G
F
–
 
 
S
e
r
u
m
 
H
G
F
 
l
e
v
e
l
s
 
↑
 
i
n
 
t
h
e
 
A
F
 
p
a
t
i
e
n
t
s
 
(
b
o
t
h
 
l
o
n
e
 
A
F
 
a
n
d
 
u
n
d
e
r
l
y
i
n
g
 
h
e
a
r
t
 
d
i
s
e
a
s
e
)
 
t
h
a
n
 
 
i
n
 
c
o
n
t
r
o
l
s
 
(
P
 
,
 
0
.
0
0
1
)
.
 
–
 
 
H
G
F
 
↓
 
s
i
g
n
i
fi
c
a
n
t
l
y
 
i
n
 
t
h
e
 
2
4
 
p
a
t
i
e
n
t
s
 
m
a
i
n
t
a
i
n
i
n
g
 
s
i
n
u
s
 
r
h
y
t
h
m
 
 
1
 
m
o
n
t
h
 
a
f
t
e
r
 
D
C
 
C
v
.
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
F
,
 
a
t
r
i
a
l
 
fi
b
r
i
l
l
a
t
i
o
n
;
 
A
F
L
,
 
a
t
r
i
a
l
 
fl
u
t
t
e
r
;
 
C
A
D
,
 
c
o
r
o
n
a
r
y
 
a
r
t
e
r
y
 
d
i
s
e
a
s
e
;
 
C
A
P
R
A
F
,
 
C
a
n
d
e
s
a
r
t
a
n
 
i
n
 
t
h
e
 
P
r
e
v
e
n
t
i
o
n
 
o
f
 
R
e
l
a
p
s
i
n
g
 
A
t
r
i
a
l
 
F
i
b
r
i
l
l
a
t
i
o
n
 
s
t
u
d
y
;
 
C
D
4
0
L
,
 
C
D
4
0
 
l
i
g
a
n
d
;
 
C
R
P
,
 
C
-
r
e
a
c
t
i
v
e
 
p
r
o
t
e
i
n
;
 
C
S
,
 
c
o
r
o
n
a
r
y
 
s
i
n
u
s
;
 
C
v
,
 
c
a
r
d
i
o
v
e
r
s
i
o
n
;
 
D
C
 
C
v
,
 
d
i
r
e
c
t
 
c
u
r
r
e
n
t
 
c
a
r
d
i
o
v
e
r
s
i
o
n
;
 
e
P
C
,
 
e
n
d
o
t
h
e
l
i
a
l
 
p
r
o
g
e
n
i
t
o
r
 
c
e
l
l
s
;
 
H
G
F
,
 
h
e
p
a
t
o
c
y
t
e
 
g
r
o
w
t
h
 
f
a
c
t
o
r
;
 
H
T
N
,
 
h
y
p
e
r
t
e
n
s
i
o
n
;
 
I
L
,
 
i
n
t
e
r
l
e
u
k
i
n
;
 
M
M
P
,
 
m
a
t
r
i
x
 
m
e
t
a
l
l
o
p
r
o
t
e
i
n
a
s
e
s
;
 
R
A
,
 
r
i
g
h
t
 
a
t
r
i
a
l
;
 
R
A
A
,
 
r
i
g
h
t
 
a
t
r
i
a
l
 
a
p
p
e
n
d
a
g
e
;
 
R
F
w
,
 
r
i
g
h
t
 
a
t
r
i
a
l
 
f
r
e
e
 
w
a
l
l
;
 
S
D
F
,
 
s
t
r
o
m
a
l
 
d
e
r
i
v
e
d
 
f
a
c
t
o
r
;
 
T
G
F
,
 
t
r
a
n
s
f
o
r
m
i
n
g
 
g
r
o
w
t
h
 
f
a
c
t
o
r
;
 
T
I
M
P
,
 
t
i
s
s
u
e
 
i
n
h
i
b
i
t
o
r
s
 
o
f
 
m
e
t
a
l
l
o
p
r
o
t
e
i
n
a
s
e
s
;
 
P
,
 
p
r
o
b
a
b
i
l
i
t
y
;
 
P
v
,
 
p
u
l
m
o
n
a
r
y
 
v
e
i
n
;
 
R
A
A
,
 
r
i
g
h
t
 
a
t
r
i
a
l
 
a
p
p
e
n
d
a
g
e
s
;
 
R
e
C
K
,
 
r
e
v
e
r
s
i
o
n
-
i
n
d
u
c
i
n
g
 
c
y
s
t
e
i
n
e
-
r
i
c
h
 
p
r
o
t
e
i
n
 
w
i
t
h
 
K
a
z
a
l
 
m
o
t
i
f
s
;
 
R
F
w
,
 
r
i
g
h
t
 
a
t
r
i
a
l
 
f
r
e
e
 
w
a
l
l
s
;
 
S
R
,
 
s
i
n
u
s
 
r
h
y
t
h
m
;
 
S
v
T
,
 
s
u
p
r
a
v
e
n
t
r
i
c
u
l
a
r
 
t
a
c
h
y
c
a
r
d
i
a
;
 
v
C
A
M
 
1
,
 
v
a
s
c
u
l
a
r
 
c
e
l
l
 
a
d
h
e
s
i
o
n
 
m
o
l
e
c
u
l
e
-
1
;
 
w
P
S
,
 
w
o
l
f
f
-
P
a
r
k
i
n
s
o
n
-
w
h
i
t
e
 
s
y
n
d
r
o
m
e
.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
88
Hadi et al
after CABG in a total of 113 CABG patients using Holter data 
from 24-hour electrocardiography (1 day before the operation 
to postoperative day [POD] 2). Similar concentrations of serum 
IL-6 were found after surgery in patients with and without AF. 
The concentrations of serum IL-8 were significantly higher at 
2 hours and on POD1 and POD2 in patients with postoperative 
AF. The concentration of serum IL-10 was significantly higher 
on POD1 in patients with postoperative AF.9
In a unique study, intraoperative biopsies from the right 
atrial appendages (RAA) and free walls (RFW) of 24 patients 
with AF undergoing a mini-Maze procedure; and 24 patients 
in SR; were investigated with qualitative and quantitative 
immunofluorescent and Western blot analyses. As compared 
with SR, all patients with AF exhibited dysregulations in 
collagen type I and type III synthesis/degradation. Tissue 
inhibitors of metalloproteinases (TIMP2) were signifi-
cantly enhanced only in RAA-AF. As compared with SR, 
  collagen VI, matrix metalloproteinases MMP2, MMP9 
and TIMP1, were significantly increased, while TIMP3 and 
TIMP4 remained unchanged in all AF groups. Reversion-
inducing cysteine-rich protein with Kazal motifs (RECK), a 
newly discovered MMPs inhibitor, was elevated in RFW as 
compared to RAA-AF (P , 0.05) and RFW-SR (P , 0.05). 
The level of TGF-β1 was higher in AF than SR.75
Atria of patients with permanent AF show evidence of cal-
pain I activation that might contribute to structural remodeling 
and contractile dysfunction, without evidence of activation of 
tissue cytokines. Atrial fibrillation is accompanied by intra-
cellular calcium overload. Goette et al76 assessed the role of 
calcium-dependent calpains and cytokines during AF. Atrial 
tissue samples from 32 patients [16 with chronic AF and 16 
in sinus rhythm (SR)] undergoing open heart surgery looking 
for atrial expression of calpain I and II, calpastatin, troponin 
T (TnT), troponin C (TnC), and cytokines [IL-1, IL-2, IL-6, 
IL-8, IL-10, TGF-β1 , and TNF-α] were determined. In these 
patients, expression of calpain I was increased during AF 
(461 ± 201% vs 100 ± 34%, P = 0.05), whereas the amounts of 
calpain II and calpastatin were unchanged. Total calpain enzy-
matic activity was more than doubled during AF (35.2 ± 17.7 vs 
12.4 ± 9.2 units, P , 0.05). In contrast to TnC, TnT levels were 
reduced in fibrillating atria by 26% (P = 0.05), corresponding 
to the myofilament disintegration seen by electron microscopy. 
Small amounts of only IL-2 and TGF-β1 mRNA and protein 
were detected regardless of the underlying cardiac rhythm.
It has been suggested that inflammation can have a role in 
the development of atrial arrhythmias after cardiac surgery, 
and that a genetic predisposition to develop postoperative 
complications exists. In 110 primary isolated coronary artery 
bypass patients, the  -174G/C IL-6 promoter gene variant was 
determined. Plasma levels of IL-6, fibrinogen and CRP were 
determined preoperatively, 24, 48, and 72 hours after surgery 
and at discharge. Heart rate and rhythm were continuously 
monitored for the first 36 to 48 hours; daily 12-lead ECGs 
were performed thereafter until discharge. GG, CT, and CC 
genotypes were found in 62, 38, and 10 patients, respectively. 
Multivariate analysis (which included genotype, age, sex, 
and classical risk factors for AF) identified the GG genotype 
as the only independent predictor of postoperative AF. The 
Table 5 Inflammatory cytokines in postoperative atrial fibrillation
Author Patients studied Cytokines studied Results
wu et al 20089 113 CABG patients IL-6, IL-8, and IL-10,  
1-day before operation 
– POD2
– IL-6 found in patients with and without AF.
–   IL-8 ↑ at 2 hrs, POD1 and POD2 in postoperative 
AF patients. Concentration of serum IL-10 ↑ on 
POD1 in postoperative AF patients.
Gunaydin et al 2007106 In a prospective randomized study,  
120 CABG patients
IL-2, C3a –   Serum IL-2 levels significantly lower in the study 
group. (P , 0.01). 
–   C3a levels significant differences in leukofiltrated 
group (P , 0.05).
Yared et al 200715 78 patients undergoing combined  
valve and CABG, randomized  
to receive either dexamethasone  
or placebo
IL-6, IL-8, IL-10, TNF-α, 
eT1, complement (C4) 
and CRP
–   No significant difference in the incidence of AF in 
placebo (41%) vs DeX groups (30%) (95% CI, 11%, 
34%, P = 0.31). 
–   DeX ↓ least 1 postoperative level of IL-6, IL-8, 
IL-10, CRP, and exhaled NO. 
– No affect on eT-1, C-4 levels.
Amar et al 2005107 A prospective study in a tertiary care 
cancer center of 131 patients (mean  
[± SD] age, 73 ± 6 years) who had 
major lung or esophageal resection
hs-CRP and IL-6 levels –   CRP and IL-6 levels ↑ (P , 0.001) in response to 
surgery.
–   Statin use associated with a 3-fold ↓ in the odds of 
developing AF (OR, 0.26; 95% CI, 0.08–0.82; P = 0.022).
Abbreviations: AF, atrial fibrillation; CABG, coronary artery bypass graft; CI, confidence interval; CRP, C-reactive protein; hs-CRP, high-sensitivity C-reactive protein;   
DeX, dexamethasone; eT, endothelin; NO, nitrous oxide; OR, odds ratio; POD, postoperative day; SD, standard deviation; TNF, tumor necrosis factor.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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latter occurred in 33.9% of GG versus 10.4% of non-GG 
patients (hazard ratio 3.25, 95% CI 1.23 to 8.62). AF patients 
had higher blood levels of IL-6 and fibrinogen after surgery 
(P = 0.001 for difference between the area under the curve). 
The -174G/C IL-6 promoter gene variant appears to modu-
late the inflammatory response to surgery and to influence 
the development of postoperative AF. These data suggest an 
inflammatory component of postoperative atrial arrhythmias 
and a genetic predisposition to this complication.
The analysis in this study is a post-hoc comparison of data col-
lected in a prospective randomized investigation, and the relatively 
small number of patients enrolled limits the statistical power of 
the study. The failure to identify as predictors of postoperative AF 
some variables that have been linked with this arrhythmia in other 
series can in fact be an expression of the reduced statistical power 
of this series. However, the fact that, despite the reduced power, the 
authors were able to clearly define a relationship between the IL-6 
gene promoter polymorphism and the occurrence of postoperative 
AF may reflect the important role of this polymorphism in the 
determination of atrial arrhythmias after coronary artery surgery. 
A further limitation is that continuous telemetry was used only 
for the first 72 hours after surgery, and from this time on patients 
were submitted to surface ECG every day, and in case of clinical 
suspicion of arrhythmia. This methodology may have resulted in 
missing some episodes of transient asymptomatic atrial arrhyth-
mia. However, it seems less likely that these episodes can have a 
significant incidence in patients who did not develop persistent 
or symptomatic atrial arrhythmia during their entire postopera-
tive course (and that have been classified in the “without atrial 
arrhythmias” group in the univariate and multivariate analysis), 
and thus, their confounding effect is likely to be minimal.77
Diagnosis and therapeutics
Prognostic value of cytokines  
in atrial fibrillation
Among AF patients, cytokines can have a prognostic 
  significance; IL-6 levels, but not prothrombin fragment 1 + 2, 
correlates with a point-based score for stroke risk in AF, even 
after oral anticogulation.78 High plasma IL-6 levels were an 
independent predictor of stroke and the composite end point 
of stroke or death.79
CRP was positively correlated to stroke risk and related to 
stroke risk factors and prognosis (mortality, vascular events). 
Soluble CD40 ligand levels were lowest in those at moderate 
to high risk of stroke and not related to prognosis. Data from 
880 subjects with AF receiving aspirin 325 mg/d (alone or 
combined with fixed inefficacious doses of   warfarin) from 
the Stroke Prevention in Atrial Fibrillation (SPAF) III clinical 
trial were analyzed. Using SPAF III stroke risk stratification 
criteria, those with moderate to high risk had the highest 
levels of CRP (Kruskal Wallis test, P , 0.001), but those 
with the highest risk had the lowest levels of soluble CD40 
ligand (P = 0.01). Similarly, CRP levels increased in a posi-
tive fashion with increasing stroke risk as estimated by the 
CHADS2 risk score and NICE risk stratification criteria, 
whereas soluble CD40 ligand levels were negatively associ-
ated with stroke risk. CRP levels were higher among patients 
with high body mass index, diabetes, hypertension, ischemic 
heart disease, peripheral vascular disease, or recent heart fail-
ure, but not those with thromboembolism. All-cause mortality 
(log rank test, P = 0.001), and vascular events (P = 0.05), 
but not stroke, were more common in patients with high 
CRP levels. Soluble CD40 ligand levels were not related to 
stroke, vascular events, or all-cause mortality.80 Another study 
suggested that plasma sCD40L may prospectively predict 
stroke in patients with AF. Levels of soluble CD40 ligand 
(sCD40L) could predict subsequent thromboembolic events 
in patients with nonvalvular AF (NVAF). In forty-four con-
secutive outpatients (mean age: 58 ± 6 years, 20 male) with 
chronic NVAF who were not receiving aspirin and had no 
thrombus or spontaneous echo contrast (SEC) on left atrium 
or left atrial appendage, sCD40L was significantly higher in 
patients with left atrial spontaneous echo contrast (LASEC) 
(0.41 ± 0.05 vs 0.16 ± 0.04 ng/mL, P = 0.02) and embolic 
events (0.74 ± 0.05 vs 0.19 ± 0.03 ng/mL, P = 0.001) than 
in those without. sCD40L levels were significantly related 
to the LASEC grade (R = 0.377, P = 0.02). In multivariable 
analysis, independent variables for SEC or thrombus for-
mation were LA diameter and sCD40L levels, whereas the 
duration of AF, independent variables for cerebrovascular 
events.80 Ferro et al found that enhanced soluble CD40L 
level is a predictor of vascular events in patients with non-
valvular AF, thus suggesting that enhanced platelet activation 
may play a role in its clinical progression. In 231 patients 
(177 [77%] had permanent or persistent AF, and 54 [23%] 
had paroxysmal AF) followed for a mean period of 27.8 ± 
8.8 months, patients with sCD40L above the median were 
4.63 times more likely to experience a vascular event (95% 
CI: 1.92–11.20) compared to patients with levels below the 
median.81
Link between inflammatory cytokines, 
adhesion molecules and risk of 
thromboembolism
AF confers a hypercoagulable state, even in the absence 
of underlying heart disease. Abnormalities of hemostasis, Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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fibrinolysis, endothelium, and platelets have all been 
described in AF, which may increase the risk of stroke 
and thromboembolism.55,66,70,82,83 Although there appears 
to be a link between inflammation and AF, one of the 
key questions is whether the observed inflammation in 
AF increases the risk of thromboembolism as has been 
demonstrated for atherosclerotic models. Plasma levels 
of CRP (P = 0.03) and soluble P-selectin (P = 0.04) and 
hematocrit (P = 0.004) were higher among patients with 
long-term AF receiving warfarin with dense SEC than 
among those without SEC on transesophageal echocar-
diography.85 The high levels of βTG and PF4 in patients 
with AF may be one explanation for the high incidence 
of thromboembolism in AF patients with and without 
valvular heart disease.84
Conway et al85 were the first to confirm this putative link 
between inflammation and complications of AF. In a small 
pilot study, they showed that elevated IL-6 levels were an 
independent predictor of the composite of stroke or death 
among a cohort of 77 high-risk AF patients. This observation 
was complemented by data from Thambidorai et al,86 which 
showed that among 104 patients with AF, transesophageal 
echocardiography-based risk factors for stroke were greater 
for patients with elevated hs-CRP compared with those with 
normal levels. Hence, there appears to be an established link 
between inflammation, AF, and thrombosis.
Markers of thrombin generation and platelet activation 
are often elevated in patients with nonvalvular AF, but it is 
unclear whether such markers usefully predict stroke. Fein-
berg et al87 assessed the relationship between prothrombin 
fragment F1.2 (F1.2), βTG, fibrinogen, and the factor V 
Leiden mutation and stroke, in AF. Specimens were obtained 
from 1531 participants in the SPAF III study. The results 
were correlated with patient characteristics, antithrombotic 
therapy, and subsequent thromboembolism (ischemic stroke 
and systemic embolism) by multivariate analysis. Increased 
F1.2 levels were associated with age (P = 0.001), female 
sex (P = 0.001), systolic blood pressure (P = 0.006), and 
heart failure (P = 0.001). F1.2 were not affected by aspirin 
use and were not associated with thromboembolism after 
adjustment for age (P = 0.18). βTG levels were higher with 
advanced age (P = 0.006), CAD (P = 0.05), carotid disease 
(P = 0.005), and heart failure (P = 0.001), lower in regular 
alcohol users (P = 0.05), and not significantly associated 
with thromboembolism. Fibrinogen levels were not signifi-
cantly related to thromboembolism but were associated with 
elevated βTG levels (P = 0.001). The factor V Leiden muta-
tion was not associated with thromboembolism (relative risk 
0.5, 95% CI 0.1–3.8). Elevated F1.2 levels were associated 
with clinical risk factors for stroke in AF, whereas increased 
βTG levels were linked to manifestations of atherosclerosis. 
In this large cohort of patients with AF who were receiving 
aspirin, F1.2, βTG, fibrinogen, and factor V Leiden were not 
independent, clinically useful predictors of stroke.
Another relatively small study88 enrolled a total of 
40 patients, 20 patients with persistent AF and 20 matched 
patients with SR quantified platelet surface expression of 
CD40/CD40L, serum levels of intercellular adhesion mol-
ecule-1 (ICAM), vascular adhesion molecule-1 (VCAM), 
hs-CRP, and monocyte chemoattractant protein-1 (MCP-1). 
Using fluorescence-activated cell sorting analysis, baseline 
CD40 expression (antibody binding capacity [ABC]) was 
increased in patients with AF (AF: 7776 6 8.46 ABC vs SR: 
7753 6 7.32 ABC; P , 0.05), whereas CD40L expression 
was not different between the two groups. In contrast to the 
effect of adenosine diphosphate, ex vivo stimulation with 
thrombin receptor activating peptide (TRAP) increased CD40 
and CD40L expression in both groups. MCP-1, hs-CRP, 
ICAM, and VCAM levels were significantly increased in 
patients with AF, reaching highest levels in patients with 
atrial thrombi. VCAM and MCP-1 were independent predic-
tors for atrial thrombi (P , 0.05, using multivariate analysis). 
In contrast to declining levels of hs-CRP, levels of ICAM, 
VCAM, MCP-1, and platelet CD40 expression remained 
elevated 5 weeks after successful electrical direct current car-
dioversion. In addition to hs-CRP, MCP-1 and VCAM may 
serve as new biomarkers, which may help to identify patients 
with an increased risk for thromboembolic events. AF is not 
an absolute prerequisite for the development of such pro-
thrombogenic alterations at the atrial endocardium, because 
it was demonstrated that pressure overload (‘‘stretch’’) per se 
causes increased expression of various endocardial proteins.89 
Therefore, in many patients with AF it has to be considered 
that the development of the arrhythmia might be a secondary 
phenomenon related to preexisting structural and thereby 
prothrombogenic alterations of the atrial myocardium and 
endocardium (‘‘endocardial remodeling’’). Thus, in some 
patients a prothrombogenic milieu persists or is imminent, 
whereas the presence of AF on the surface ECG may serve 
only as a marker for such alterations. This may help to explain 
the finding that VCAM and MCP-1 levels remained elevated 
for weeks after successful cardioversion of AF, because 
the underlying structural abnormalities of the atria are not 
instantaneously normalized by restoration of sinus rhythm. Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Of note, MCP-1 and VCAM levels are independent   predictors 
for atrial thrombi, which suggest a clinical importance for 
this finding. MCP-1 and VCAM appear as biomarkers, 
which may help identify patients with an increased risk for 
thromboembolic events.
Plasma levels of sCD40L are elevated in patients with AF, 
and are related to levels of VEGF, angiopoietin (Ang)-2, and 
tissue factor (TF). This interaction among platelets, angio-
genic markers, and TF may play a role in the generation of 
the prothrombotic state associated with AF. In 59 patients 
with chronic AF measuring plasma levels of soluble CD40 
ligand (sCD40L [an index of platelet activation]) and TF 
[an index of coagulation], as well as the angiogenic factors, 
VEGF, angiopoietin (Ang-1, and Ang-2) by enzyme-linked 
immunosorbent assay, AF patients had significantly higher 
levels of sCD40L (P = 0.038), VEGF (P = 0.023), and 
Ang-2 (P , 0.001), but not Ang-1 (P = 0.363), compared to 
control subjects. In nonanticoagulated AF patients (N = 28), 
TF   levels were also higher (P = 0.043), in addition to high 
sCD40L, VEGF, and Ang-2, compared to control subjects. 
Among AF patients, sCD40L levels correlated strongly 
with levels of VEGF (R = 0.919; P , 0.001) and Ang-2 
(R = 0.546; P = 0.002). VEGF levels were significantly cor-
related with levels of Ang-2 (R = 0.490; P , 0.001) and TF 
(R = 0.298; P = 0.044). In multivariate regression analysis, 
sCD40L levels were independently associated with levels of 
VEGF (P = 0.003) and Ang-2 (P = 0.005).90
Patients with chronic AF have high TF levels, in keeping 
with the prothrombotic state associated with this arrhythmia. 
The relationships between TF and VEGF and its receptor 
sFlt-1 in AF suggest a possible role for VEGF in the hyper-
coagulable state found in AF, as seen in malignancy and 
atherosclerosis. Chung et al91 studied 25 patients with AF 
(20 men; mean ± SD age, 62 ± 13 years) who were compared 
with two control groups in sinus rhythm: 30 healthy control 
subjects (17 men; mean age, 60 ± 9 years) and 35 patient 
control subjects with CAD (CAD; 27 men; mean age, 
60 ± 12 years). Plasma levels of TF, VEGF, and the VEGF 
receptor sFlt-1 were measured by enzyme-linked immu-
nosorbent assay. VEGF, sFlt-1, and TF were significantly 
different between the three groups, with abnormal levels 
in AF and CAD patients compared with control subjects 
(P , 0.001, P = 0.022, and P = 0.008, respectively). Among 
the AF patients, TF levels were significantly correlated 
with VEGF (P , 0.001) and sFlt (P = 0.006) levels. Only 
TF and VEGF levels were significantly correlated in CAD 
patients (P , 0.02). There were no significant correlations 
among the healthy control subjects. This study is limited by 
its   cross-sectional design but was adequately powered to 
undertake the main analyses in relation to patients with AF. 
In this study AF patients were also taking warfarin, but there 
is no evidence to suggest that warfarin influences the levels of 
the indexes measured. Furthermore, a cross-sectional design 
of this study helps only to explore associations; no causal-
ity is implied because only a prospective cohort study with 
large numbers of subjects with AF can confirm the natural 
history of the indexes measured in the short, medium, and 
long term in relation to interventions (cardioversion, intro-
duction of antithrombotic therapy, etc), as well as morbidity 
and mortality.
Increased plasma IL-6, CRP, and plasma viscosity sup-
port the case for the existence of an inflammatory state among 
“typical” populations with chronic AF. These markers of 
inflammation are related to indices of the prothrombotic state 
and may be related to the clinical variables of the patients 
(underlying vascular disease and co-morbidities), rather 
than simply to the presence of AF itself).56 FXIII Val34-
Leu polymorphism was independently associated with IL-6 
levels in AF. The Leu34 allele may potentially influence 
the prothrombotic state in these patients by modulating the 
inflammatory state.92
The endocardial surface could be considered as part 
of the systemic endothelium, which could be a source of 
E-selectin, but the data differentiating between the two in 
relation to E-selectin are limited. However, the expression 
of E-selectin in endocardium has been studied in relation to 
human cardiac allograft rejection, but these studies demon-
strated a little or no expression of E-selectin in endocardium 
specimens.93–95 Kamath et al studied 122 patients (mean 
age ± SD = 71 ± 9 years; 65 men) with chronic AF of 6 weeks’ 
duration: 34 were not on antithrombotic therapy, 30 were 
taking aspirin (75 to 300 mg/d), and 58 were fully anticoagu-
lated with warfarin. P-selectin per platelet (pP-selectin) was 
compared with soluble P-selectin (sP-selectin) and plasma 
βTG levels (enzyme-linked immunosorbent assay). Results 
were compared with those of 23 healthy controls (mean 
age ± SD= 74 ± years; 7 men) in sinus rhythm. pP-selectin 
was significantly lower in AF patients on no antithrombotic 
therapy (P = 0.03) than in healthy controls, but sP-selectin 
and βTG levels were not significantly different and did not 
differ in patients taking aspirin or warfarin. However, pP-
selectin was lower in patients with AF on aspirin than in 
those on warfarin (P = 0.05). pP-selectin/sP-selectin cor-
related significantly in healthy controls (R = 0.47, P = 0.03) Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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but inversely (R = 0.43, P = 0.03) in AF patients on no 
  antithrombotic therapy. The results from this study suggest 
that even though P-selectin is expressed on the surface of 
platelets in AF, the absolute pP-selectin level is low. Further-
more, whether the absolute amount of P-selectin within a 
platelet reflects platelet activation is unclear. The finding of 
lower pP-selectin in AF than in healthy controls could poten-
tially be explained in two ways.96 First, activated platelets in 
AF result in the fusion of granules with the platelet surface, 
followed by degranulation. This results in the expression 
of P-selectin on the platelet surface and possible release 
into the plasma. While the amount of P-selectin depleted 
may be great enough to result in a significant decrease in 
pP-selectin, it may not be high enough to make a significant 
difference to the larger plasma reserve of sP-selectin. This 
is further supported by the finding that pP-selectin showed 
a negative significant correlation with sP-selectin in patients 
with AF and not in healthy controls. Therefore, after platelet 
activation, P-selectin may be depleted in the platelets and 
may increase in the plasma. Second, it is theoretically pos-
sible that P-selectin, which is expressed on the surface of 
the platelet on activation, changes its configuration and is 
detected by the specific antibody during flow cytometry. 
Since the ELISA was used to detect pP-selectin, it is pos-
sible that the antibody has detected only granule P-selectin, 
not recognizing the membrane P-selectin. This concept is 
also supported by Semenov et al who demonstrated that the 
polyclonal antibody they used in their study to detect sP-
selectin in a platelet had lower reactivity toward membrane 
P-selectin. Furthermore, 90% of the P-selectin in the lysate 
is accounted for by the membrane P-selectin and 10% by the 
sP-selectin in the platelet granules membrane.97
Aspirin has previously been shown to have no significant 
effect on sP-selectin levels.98–100 Aspirin appears to decrease 
the amount of pP-selectin in patients with AF in comparison 
to those on adjusted-dose warfarin. Although previous studies 
have suggested a cyclooxygenase-independent mechanism 
for the production of P-selectin, whether pP-selectin is a 
product of pathways involving cyclooxygenase remains to 
be seen.
Roldán et al101 studied 191 consecutive patients 
(98 male; mean age 72.3 ± 9.2 years) with chronic nonrheu-
matic AF who were not on anticoagulant therapy. Plasma 
IL-6, endothelial activation (soluble E-selectin [sEsel]) 
and prothrombin fragment 1 + 2 (F1+2) were measured 
by ELISA. Research indices were compared to 74 controls 
in sinus rhythm matched for age and sex. In 43 patients 
with AF, the effects of introducing anticoagulation (INR 
2.0–3.0) were also studied. Patients with AF had elevated 
levels of F1 + 2 (P , 0.001) and IL-6 (P = 0.045), but 
not sEsel. There was no significant correlation between 
F1 + 2 and IL-6. In multivariate analysis, only F1+2 lev-
els were independently associated with the presence of 
AF (P = 0.001). After oral anticoagulation, plasma levels 
of F1 + 2 and sEsel were significantly decreased (both 
P , 0.01). High levels of IL-6 in AF suggest an inflam-
matory state, which appears to be more related to clinical 
variables of the patients, rather than to the presence of 
AF per se. There was no association of inflammation with 
sEsel or the presence of abnormal thrombogenesis (high 
F1 + 2 levels) in AF. Moreover, no changes in IL-6 levels 
were found despite the reduction of the other markers by 
oral anticoagulant therapy. This study, which investigated a 
fairly large cohort of patients with AF, who had documented 
AF of .4 weeks duration, is limited by its cross-sectional 
design, which only allows exploring associations, and no 
causality is implied, as only a prospective cohort study with 
large numbers of subjects with AF can confirm the natural 
history of the indices measured in the short-, medium-, and 
long-term. Indeed, IL-6 is a key inflammatory cytokine, and 
is normally present in low concentrations (but increases 
with infection, trauma, stress and age, etc); thus, an ability 
to determine the independent relationship between IL-6 and 
AF would certainly require further longitudinal studies, as 
well as prolonged periods of ‘exposure’ to the particular 
disease state.
Therapeutic implications
Several animal studies have shown the relation between 
inflammatory cytokines and atrial tachyarrythmias includ-
ing AF. Rabbits subjected to ventricular tachypacing at 380 
to 400 beats per minute (bpm) for 4 weeks in the absence 
and presence of treatment with pioglitazone, candesartan, 
and combined pioglitazone and candesartan were assessed 
by electrophysiologic study102 together with atrial fibrosis 
measurements, and cytokine expression analyses. Both 
pioglitazone and candesartan reduced TGF-β1, TNF-α, 
and activated extracellular signal-regulated kinase expres-
sion similarly, but neither affected p38-kinase nor c-Jun 
N-terminal kinase activation. The effects of combined 
pioglitazone and candesartan therapy were not significantly 
different from the effects of pioglitazone or candesartan 
alone. Pioglitazone reduced the duration of AF (3.5 ± 0.2 
seconds, P , 0.05) and attenuated atrial structural remod-
eling, with significant reductions in interatrial activation 
time (50 ± 2 ms vs 41 ± 2 ms, P , 0.05), and atrial fibro-Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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sis (16.8% ± 0.8% vs 10.9% ± 0.7%, P , 0.05; control 
1.6% ± 0.2%); effects comparable to those of   candesartan 
(duration of AF: 3.0 ± 0.2 seconds; activation time 44 ± 2 
ms; fibrosis: 9.4% ± 0.6%).
Chronic AF acutely upregulates CD40 expression as well 
as platelet adhesion to the endocardium. Simvastatin is effec-
tive in modulating this expression, thus it may potentially 
contribute to reduction of the risk of intraatrial thrombus 
formation. This issue has been explored in experiments on 
right atrial segments obtained before the onset of cardiopul-
monary bypass, in either presence or absence of 5 micrM 
simvastatin. AF was associated with a significant increase of 
endocardial CD40 expression (293.1 ± 55.1 pg/mL vs 230.9 ± 
53.3 pg/mL; P , 0.01), and platelet-endocardial adhesion 
compared with sinus rhythm (10.8 ± 2.2 vs 5.2 ± 1.3 platelet 
CD41 AU; P , 0.01). At immunofluorescence, about 62% 
of fibrillating endocardium was covered by platelets, com-
pared with 12% with sinus rhythm. Addition of simvastatin 
significantly reduced CD40 expression as well as platelet 
adhesion to fibrillating atria. Its efficacy was not reversed 
by the addition of mevalonic acid.103
The observed inflammatory response is consistent with 
histopathologic information on ablation-induced inflamma-
tory activation and is supposed to contribute to the phenom-
enon of early AF recurrence after ablation.44,82 Although it 
is not yet known whether inflammation acts as an initiator 
or is just a consequence of AF, there is evidence that CRP-
lowering therapies could prevent AF.54,62 Statins as well as 
angiotensin-converting enzyme inhibitors (ACE-Is) and 
angiotensin receptor blockers (ARBs) have the potential 
to modulate inflammatory pathways and could therefore 
reduce the susceptibility to AF after ablation in general, and 
attenuate the acute inflammatory response in the early post 
ablation period.
Furthermore, CRP-lowering with atorvastatin appears 
to be effective in eliminating PAF during daily life in a 
significant proportion of patients. In a prospective study of 
80 patients with proven PAF, 40 patients were randomized 
to placebo (placebo group) and 40 to atorvastatin (treatment 
group). Plasma CRP levels and ambulatory monitoring were 
repeated after 4 to 6 months of therapy. The two groups 
were comparable with respect to baseline characteristics, 
baseline number of episodes of PAF, and baseline plasma 
CRP levels. The treatment group had lower median CRP 
levels and exhibited a highly significant reduction in 
PAF (P , 0.001).   Paroxysmal AF completely resolved in 
26 (65%) of 40 patients in the treatment group versus four 
(10%) of 40 in the placebo group. By logistic regression, 
treatment with atorvastatin was an independent predictor of 
PAF resolution.63
Treatment of CHF canines with the antifibrotic drug pir-
fenidone (PFD) resulted in an attenuation of arrhythmogenic 
left atrial remodeling, with a significant reduction in left atrial 
conduction heterogeneity index, left atrial fibrosis and AF 
duration. Immunoblotting studies demonstrated the drug’s 
effects on multiple cytokines, including a reduction in TGF-1 
expression.104 In transgenic mice with targeted overexpres-
sion of TNF in the cardiac compartment, sustained inflam-
matory signaling contributed to atrial structural remodeling 
and down regulation of connexin 40 that was associated with 
an increased prevalence of atrial arrhythmias.105
Leukofiltration and coating significantly reduce the inci-
dence, ventricular rate, and duration of AF after CABG via 
modulation of systemic inflammatory response and platelet 
preservation in high risk groups. In a prospective random-
ized study, 120 patients undergoing CABG were allocated 
into two groups (N = 60). Group 1 – polymethoxyethylacry 
late-coated circuits + leukocyte filters (Terumo, USA); 
Group 2 – control: uncoated circuits (Terumo, USA). Each 
group was further divided into three subgroups (N = 20) with 
respect to low (Euroscore 0-2), medium (3–5), and high (6+) 
risk patients, serum IL-2 levels were significantly lower in 
the study group at T4 and T5 (P , 0.01). C3a levels showed 
significant differences in the leukofiltrated group at T4 and 
T5 (P , 0.05).106
CRP and IL-6 levels increased significantly (P , 0.001) 
in response to surgery (major lung or esophageal 
resection)107 and dexamethasone did not affect the inci-
dence of AF in patients undergoing combined CABG and 
valve surgery.108 However, it did modulate the release of 
several inflammatory and acute-phase response mediators 
that are associated with adverse outcomes. In this study, 
78 adult patients undergoing combined valve and CABG 
surgery were randomized to receive either dexamethasone 
or placebo, No significant difference in the incidence of 
postoperative AF was found between the placebo (41%) 
and dexamethasone groups (30%) (95% confidence inter-
val [-11%, 34%]; P = 0.31). Dexamethasone significantly 
reduced at least 1 postoperative level of IL-6, IL-8, IL-10, 
CRP, and exhaled nitrous oxide. Dexamethasone did not 
affect endothelin-1 or C-4 levels. On the other hand the 
preoperative use of statins was associated with a protec-
tive effect against postoperative AF, independent of CRP 
levels.107 In contrast to AF in the general population, early 
markers of inflammation did not predict the postoperative 
occurrence of AF.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Future perspectives
The future will witness increasing interest in finding reliable 
methods of testing the prognostic utility of cytokines in dif-
ferent types of AF. Several large noninvasive and invasive 
studies are needed to determine the predictive value of cytok-
ines as a potential predictor of AF and the associated risk of 
thromboembolism. Establishing cytokines as prognostically 
useful and potentially as therapeutic targets may change 
our understanding of AF and revolutionize our treatment 
strategy for one of the most difficult sustained arrhythmias 
encountered in clinical practice.
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